Eton Pharmaceuticals, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Eton Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2020-12-31 was $21.03M.
- Eton Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2020-09-30 was $0.00.
- Eton Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2020-06-30 was $297.00K.
- Eton Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2020-03-31 was $7.46M.
- Eton Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2024 was $7.00M.
- Eton Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2020 was $28.78M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $7.00M 10-K · filed 2026-03-19 | |
| 2020-12-31 | $21.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $28.78M 10-K · filed 2023-03-16 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-16 | |
| 2020-06-30 | $297.00K 10-Q · filed 2021-08-16 | |
| 2020-03-31 | $7.46M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |